Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9251921 | 0.98 | NPC1 (0.47) | NPC1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9128054 | 0.98 | NPC1 (0.47) | NPC1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17916210 | 0.95 | NPC1 (0.39) | NPC1ALDH1A1CA12CA1CA2 | |
| SCHEMBL10186897 | 0.90 | — | — | |
| SCHEMBL24779960 | 0.85 | NPC1 (0.44) | NPC1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL19576091 | 0.82 | HCRTR2 (0.33) | ALDH1A1 | |
| SCHEMBL24508705 | 0.82 | NPC1 (0.36) | NPC1 | |
| SCHEMBL1298498 | 0.81 | NPC1 (0.41) | NPC1LNPEP | |
| SCHEMBL3186526 | 0.81 | ALDH1A1 (0.34) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL22152196 | 0.80 | PIK3CD (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-5401768-A | Prostaglandin derivative, antiulcer, hypotensive, anticoagulant | TORAY INDUSTRIES, INC. (JP) | 1995-03-28 | — | — | US | disclosed |
| EP-0365678-B1 | 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF | TORAY INDUSTRIES (JP) | 1994-01-05 | — | — | EP | disclosed |
| EP-0389162-B1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES (JP) | 1993-12-08 | — | — | EP | disclosed |
| US-5086071-A | Improved chemical stability and ppotent in vivo | TORAY INDUSTRIES, INC. (JP) | 1992-02-04 | — | — | US | disclosed |
| EP-0232776-B1 | 2,5,6,7-TETRANOR-4,8-INTER-M-PHENYLENE PGI2 DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1990-10-24 | — | — | EP | disclosed |
| EP-0389162-A1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1990-09-26 | — | — | EP | disclosed |
| EP-0365678-A1 | 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1990-05-02 | — | — | EP | disclosed |
| US-4775692-A | ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT | TORAY INDUSTRIES, INC. (JP) | 1988-10-04 | — | — | US | disclosed |
| EP-0232776-A2 | 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1987-08-19 | — | — | EP | disclosed |
| EP-0004335-A2 | Prostacyclin analogs, process and intermediates for their preparation and their use as medicines | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-10-03 | — | — | EP | disclosed |
| EP-0001270-A1 | Analogues of prostacycline, methods for their preparation and their use in the treatment of circulatory diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX3, P2RX7, P2RX2 | NPC1 1114/4885ALDH1A1 2404/4885CYP1A2 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.